Get started
Author

Harkeran K. Jandu

Observed names: H. Jandu, Jandu, Harkeran
ORCID: 0000-0001-6978-8092
Observed ORCID: 0000-0001-6978-8092
OpenAlex ID: A5072813532
Genome-wide association study of treatment-related toxicity two years following radiotherapy for breast cancer
2023 · Harkeran K. Jandu, Colin D. Veal, et al. · Radiotherapy and Oncology · 23
PDF
No Association Between Polygenic Risk Scores for Cancer and Development of Radiation Therapy Toxicity
2022 · Gillian C. Barnett, Sarah L. Kerns, et al. · International Journal of Radiation Oncology*Biology*Physics · 7
PDF
Inherited predisposition to increased systemic inflammation predicts a broad class of disease phenotypes
2026 · Harkeran K. Jandu, Ayokunle Olowofela, et al. · Human Genetics and Genomics Advances
Prediction of Side Effects from Breast Radiation Therapy—Integration of Clinical and Genomic Data
2026 · Abeer Al Janapy, Adam J. Webb, et al. · International Journal of Radiation Oncology*Biology*Physics
Genetic determinants of fatigue up to 2 years after radiotherapy in prostate cancer patients
2026 · Philipp Heumann, Miguel E. Aguado-Barrera, et al. · Nature Communications
PDF
Predictors of long-term adverse quality of life following breast cancer treatment – Insights from the REQUITE cohort study
2024 · H. Jandu, C. Veal, et al. · European Journal of Cancer
Genome wide association study of long-term patient-reported outcomes following radiotherapy for breast cancer – results from the REQUITE cohort study
2022 · H. Jandu, C.D. Veal, et al. · European Journal of Cancer
Works count: 8
Citation count: 30
H-index: 2
I10-index: 1
Year
Topic
Type